Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2015

View Archived Issues

PROTACs: tagging disease-associated proteins for degradation

C9orf72 knockout insufficient to cause motor neuron diseases in mice

PeptiDream and Teijin agree discovery collaboration

Bone Therapeutics initiates trial of ALLOB for minimally invasive revision spinal surgery

Intrexon and Ziopharm Oncology form exclusive channel collaboration in GvHD

PPOX identified as a new target for colorectal cancer therapy

Aldeyra Therapeutics enrolls first patient in phase IIa trial of NS-2

Novan Therapeutics reports IIb trial data for SB-204 for in acne vulgaris

Macrophage Therapeutics produces first two immunoconstructs

BLU-554 receives FDA orphan drug designation for hepatocellular carcinoma

Polyphor/Roche macrocyclic peptide to combat multidrug-resistant bacterial infections

PTC Therapeutics submits variation for new indication in Europe for Translarna

BiondVax begins phase IIb trial of universal flu vaccine in Europe

SEQ-9, a novel macrolide for the treatment of tuberculosis

Zosano discontinues daily ZP-PTH and resumes development of weekly formulation

Novel 2-pyridone antibacterials to treat Gram-negative bacterial infections

AMO Pharma raises funds to advance clinical-stage candidates and expand pipeline

reMYND develops new compounds for protein-misfolding disorders

iTeos Therapeutics describes TDO2 inhibitors

Tyme submits phase II IND application for SM-88

Incretin effect identified as a predictor of prediabetes in women with previous GDM

Trillium advances TTI-621 towards phase I trials

Merck & Co. presents SYK inhibitors

FDA awards QIDP designation to Ixogel for prevention of Lyme disease

Ignyta initiates phase II trial of entrectinib

BioMarin to acquire global rights to Kuvan and pegvaliase from Merck Serono

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.